Showing results (691-700 of 805) with videos related to

Sort By:
Pageof 81
Shock (Augusta, Ga.)|December 22, 2025
Measurement of central nervous system related biomarkers in plasma of burn patientsAndrew J Hoisington, Christopher E Stamper, Molly Sullan, et al.
Digestive Diseases and Sciences|January 5, 2005
Improved methods for extracting RNA from exfoliated human colonocytes in stool and RT-PCR analysisFarid E Ahmed, Stephanie I James, Donald T Lysle, et al.
Journal of Thrombosis and Haemostasis : JTH|April 2, 2015
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN StudyC W Francis, C M Kessler, S Z Goldhaber, et al.
Journal of Thrombosis and Haemostasis : JTH|January 29, 2023
The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolismLucia Caiano, Michael J Kovacs, Alejandro Lazo-Langner, et al.
Journal of Burn Care & Research : Official Publication of the American Burn Association|January 12, 2022
Age and Injury Size Influence the Magnitude of Fecal Dysbiosis in Adult Burn PatientsKiran Dyamenahalli, Kevin Choy, Daniel N Frank, et al.
Journal of Cardiac Failure|June 28, 2020
Enhanced Response to Drug-Induced QT Interval Lengthening in Patients with Heart Failure with Preserved Ejection FractionJames E Tisdale, Heather A Jaynes, Brian R Overholser, et al.
Thrombosis and Haemostasis|June 29, 2007
The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trialKarim Abou-Nassar, Michael J Kovacs, Susan R Kahn, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 30, 2008
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapyMarc A Rodger, Susan R Kahn, Philip S Wells, et al.
Pageof 81